Avulux, the innovator behind the only clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks, and BluTech, a longstanding industry leader in the light protection space, today announced a direct partnership under which BluTech will manufacture the next generation of Avulux migraine and light sensitivity lenses. These lenses will fully replace the current generation of Avulux lenses starting on January 5, 2026, improving lens quality in several important ways while maintaining the unique spectral curve patients and providers trust.
After a rigorous research and development process undertaken jointly by both organizations, the next generation of Avulux lenses will leverage BluTech’s unique, proprietary lens composition to greatly improve Abbe value from 29 to 38, resulting in clearer, sharper vision with less color fringing or blur, improved contrast, and reduced eye strain. This new generation of Avulux lenses will also feature improved cosmetic appearance and better color consistency from lens to lens, regardless of geometry, thickness, material, or other factors. These lenses will also be significantly more workable by both optical labs and independent eyecare providers, with higher heat tolerances that can withstand virtually all lab processes – allowing Avulux lenses to be more compatible with the widest possible range of coatings. Avulux and BluTech have also begun work on both a polarized and photochromic lens, both of which are anticipated to be available in the second quarter of 2026.
BluTech launched its first light management lens in 2017, after extensive testing with over fifty doctor’s offices. Since then, they have established themselves as a trusted partner in providing solutions industry-wide for addressing harmful light.
“BluTech is proud to support eyecare providers through extensive and synergistic partnerships with emerging lens innovations like Avulux,” says Greg Naes, President of BluTech. “Both organizations are committed to supporting the industry with best-in-class solutions, and both organizations have light management products with demonstrable patient impact. This is an exciting partnership.”
The Avulux lens is the only lens that has been clinically proven for people living with migraine and light sensitivity. In a 2020 double blind, randomized, placebo-controlled study conducted by an independent clinical research organization, the Avulux lens achieved both clinical and statistical significance when compared to a clear placebo lens.
“We are thrilled to partner with BluTech on the most significant product improvement in the history of our company,” said Dr. Charles Posternack, Chief Executive Officer, Avulux. “This partnership will give every lab and eyecare provider the opportunity to provide Avulux lenses, ensuring that migraine sufferers everywhere will have access this life-changing technology.”
About Avulux
Actively supporting people living with migraine and light sensitivity is central to everything Avulux does. Their lenses incorporate a multi-band precision optical filter that works by filtering up to 97% of harmful blue, amber, red light while allowing in soothing green light. In a 2020 double blind, randomized, placebo-controlled study conducted by an independent clinical research organization, the Avulux lens achieved both clinical and statistical significance when compared to a clear placebo lens. For more information about Avulux, visit ecp.avulux.com.
About BluTech
BluTech’s mission is twofold: to protect long-term eye and overall health and to educate professionals and consumers alike about embracing the era of blue light. BluTech began its journey into the world of blue light back in 2012, well before blue light became a popular topic. BluTech’s continuous research to evolve and improve harmful light protection makes BluTech one of the most prominent innovators in the light protection space. For more information about BluTech, visit blutechlenses.com.
Media Contacts
Avulux: Ari Avila
aavila@avulux.com
BluTech: Betsy Ley
bley@blutechlenses.com
